

TriageTB

Factsheet

**Acronym**

TriageTB

Full Title

Field evaluation of a point-of-care triage test for active tuberculosis

Programme

EDCTP II/2nd. European & Developing Countries Clinical Trials Partnership Programme

Contract Number

Grant Agreement N° RIA2018D-2499

Abstract

The goal of TriageTB is to field-validate a rapid point-of-care triage test for active tuberculosis (TB) that can be conducted in a laboratory-free manner. Such a test could transform the TB diagnostic landscape.

Most of the experts from Africa and Europe behind this project have already successfully worked together in the two previous EDCTP-funded initiatives AE-TBC ("African European Tuberculosis Consortium", July 2010 - December 2013) and ScreenTB ("Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB", April 2016 – July 2019). They have now teamed up with the Foundation of Innovative New Diagnostics (FIND) to further improve the test and ensure its global applicability and prepare its commercialization.

The TriageTB project will have a duration of four years and started in October 2019.

The project's vision is to develop a triage test, or rule-out test, with low complexity that can be performed at the point-of-care (POC) in a laboratory-free manner by minimally trained health care workers, would identify those patients with the highest risk for active TB. The test would quickly rule out the majority patients who do not suffer from TB but have other respiratory illnesses such as acute upper or lower respiratory tract infections or exacerbation of chronic obstructive pulmonary disease. A positive test result would indicate a high likelihood for active TB and i) focus health worker attention on this smaller number of patients and ii) might increase adherence of patients as well as primary health care workers to the diagnostic workup process, which includes return visits for GeneXpert or culture results, allowing a definitive diagnosis and quick initiation of treatment.

Specifically, the aim is to refine and prospectively evaluate the performance of a POC multi-biomarker test (MBT) as triage test on fingerstick blood utilizing upconverting phosphor technology at three African sites (Uganda, The Gambia and South Africa) in a laboratory-free manner. Building on extensive experience gained during previous EDCTP-funded projects, the project is furthermore based on strong biomarker data, an advanced user-friendly, rapid, multiplex test device and implementation expertise supported through EDCTP2.

The project will be implemented in three phases:

1: validation of existing signature on stored samples from outside Africa

2: refinement/locking of signature

3: large-scale prospective field testing at peripheral health care clinics in Africa

TriageTB is implemented by a team of passionate people with very complementary skills but one common goal: to make a real difference in the lives of patients. The project is coordinated by Prof. Gerhard Walzl from Stellenbosch University (SUN), South Africa and managed by LINQ management GmbH from Berlin, Germany. Other collaborators include the London School of Hygiene and Tropical Medicine (UK), the Medical Research Council Unit The Gambia at LSHTM (The Gambia), Makerere University (Uganda), Leiden University Medical Center (The Netherlands), and the Foundation for Innovative New Diagnostics (Switzerland).

Duration

48 months (01/10/2019 - 30/09/2023)

Project Funding

3,291,740 EUR

Coordinator

Prof. Gerhard Walzl

Stellenbosch University

Tel: +27 21 9389158

Email: gwalzl@sun.ac.za

Partners

London School of Hygiene and Tropical Medicine, UK

Medical Research Council Unit The Gambia at LSHTM, The Gambia

Makerere University, Uganda

LINQ management GmbH, Germany

Leiden University Medical Center, The Netherlands

Foundation for Innovative New Diagnostics, Switzerland

Project Management

LINQ management GmbH

Julia Buech

Phone: +49 (0)30 300 96442

Email: j.buech@linq-management.com

Project Website

www.triagetb.com